<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7431281\results\search\testTrace\results.xml">
  <result pre="with preexisting health conditions. However, the potential pathogenesis of SARS-CoV-2" exact="infection" post="in humans is still unknown. The dysregulated/exuberant immune response"/>
  <result pre="pandemic of COVID-19. In this article, we highlighted the pharmacological" exact="treatment" post="strategies for COVID-19 and purposed the therapeutic targets for"/>
  <result pre="the development of vaccines or anti-viral drug molecules against SARS-CoV-2" exact="infection" post="in humans. Keywords Novel coronavirus disease COVID-19 SARS-CoV-2 Anti-viral"/>
  <result pre="2003 [6, 7]. MERS-CoV was first reported to cause human" exact="infection" post="in Saudi Arabia in 2012, where it remains a"/>
  <result pre="breath, fatigue, and, in a small population of patients, gastrointestinal" exact="infection" post="symptoms to acute respiratory distress and pneumonia [15â€&quot;17]. The"/>
  <result pre="presence of ageusia and anosmia in the patients with COVID-19" exact="infection" post="[18â€&quot;20]. The reproductive number of SARS-CoV-2 infection is estimated"/>
  <result pre="patients with COVID-19 infection [18â€&quot;20]. The reproductive number of SARS-CoV-2" exact="infection" post="is estimated to be 2â€&quot;3 [11], and the elderly"/>
  <result pre="disease, lung disease, cancer, etc. are more susceptible to severe" exact="infection" post="and fatality [21â€&quot;24]. Currently, there is no clinically approved"/>
  <result pre="[21â€&quot;24]. Currently, there is no clinically approved drug/vaccine for the" exact="treatment" post="of this disease. All the health organizations across the"/>
  <result pre="higher than the number of confirmed deaths, due to limited" exact="testing" post="and problems in the attribution of the cause of"/>
  <result pre="COVID-19 is still going on. Currently, various preventive measures including" exact="social distancing," post="hand sanitization, avoiding non-essential international/national travels, use of facial"/>
  <result pre="etc. are used to restrict the further transmission of SARS-CoV-2" exact="infection" post="across the world. Several pharmacological treatment possibilities are being"/>
  <result pre="further transmission of SARS-CoV-2 infection across the world. Several pharmacological" exact="treatment" post="possibilities are being explored to treat this infection. In"/>
  <result pre="other viral infections is now being followed to treat SARS-CoV-2" exact="infection" post="and might have gained significant improvement in pneumonia-associated symptoms"/>
  <result pre="Interventions Locations 1 Maternal-Foetal Transmission of SARS-Cov-2 Recruiting Maternal fetal" exact="infection" post="transmission COVID-19 SARS-CoV 2 Diagnostic test: diagnosis of SARS-Cov2"/>
  <result pre="Recruiting Maternal fetal infection transmission COVID-19 SARS-CoV 2 Diagnostic test:" exact="diagnosis" post="of SARS-Cov2 by RT-PCR and IgG, Ig M serologies"/>
  <result pre="Not yet recruiting COVID-19 Diagnostic test: diagnostic tests for COVID-19" exact="infection" post="4 The Role of a Private Hospital in Hong"/>
  <result pre="Device: performance evaluation study of RealDetect RT-PCR Kit for COVID-19" exact="detection" post="â€¢ Institute of Epidemiology, Disease Control and Research (IEDCR),"/>
  <result pre="Study Enrolling by invitation COVID-19 Other: COVID-19 PCR and serology" exact="testing" post="â€¢ Duke CTSI Translational Population Health Office, Kannapolis, NC,"/>
  <result pre="and Treatment of COVID-19 Complications Enrolling by invitation COVID-19 Coronavirus" exact="infection" post="SARS-CoV-2 Complications Other: complex diagnostic panel â€¢ Silesian Centre"/>
  <result pre="Patients with Active Symptomatic COVID 19 Infection (FALP-COVID) Recruiting COVID-19" exact="infection" post="Cancer patients General population Biological: convalescent plasma from COVID-19"/>
  <result pre="Hospital Department Enrolling by invitation COVID-19 Diagnostic test: COVID-19 test," exact="polymerase chain reaction" post="for SARS-CoV-2 â€¢ Rigshospitalet University Hospital of Copenhagen, Copenhagen,"/>
  <result pre="Antibody Levels in an Hospital Population Recruiting COVID-19 Diagnostic test:" exact="detection" post="of anti-COVID-19 antibody level â€¢ Humanitas Rozzano/San Pio X,"/>
  <result pre="with COVID-19: a Pilot Study Not yet recruiting Coronavirus Coronavirus" exact="infection" post="Drug: plasma â€¢ Universidad del Rosario, Bogota, Cundinamarca, Colombia"/>
  <result pre="intervention planned due to the observational study designâ€&quot;only a diagnostic" exact="testing" post="â€¢ University of Ljubljana, Ljubljana, Slovenia 30 Incidence of"/>
  <result pre="USA 31 Novel COVID-19, a National Analysis Recruiting COVID-19 Other:" exact="prevalence" post="of COVID-19 â€¢ Assiut University Hospitals, Assiut, Egypt 32"/>
  <result pre="Label, Parallel, Controlled Clinical Study Not yet recruiting Coronavirus Coronavirus" exact="infection" post="Drug: plasma Drug: hydroxychloroquine â€¢ Universidad del Rosario, Bogota,"/>
  <result pre="Health System COVID-19 Patient Registry Not yet recruiting COVID-19 Other:" exact="treatment" post="for COVID-19 â€¢ Clinical Research Institute Methodist Health System,"/>
  <result pre="Health Large-Scale Automated Serologic Testing for COVID-19 Recruiting COVID-19 Coronavirus" exact="infection" post="Severe acute respiratory syndrome coronavirus 2 Diagnostic test: EUROIMMUN"/>
  <result pre="Clinical Characteristics and Outcomes of Pediatric COVID-19 Recruiting COVID-19 SARS-CoV-2" exact="infection" post="Pediatric ALL Pneumonia, viral Pandemic response Other: exposure (not"/>
  <result pre="Pediatric ALL Pneumonia, viral Pandemic response Other: exposure (not intervention)â€&quot;SARS-CoV-2" exact="infection" post="â€¢ University of Calgary/Alberta Childrenâ€™s Hospital, Calgary, Alberta, Canada"/>
  <result pre="Detection Enrolling by invitation COVID-19 SARS-CoV-2 Device: Rapid Onsite COVID-19" exact="detection" post="â€¢ University of Wisconsin, Madison, WI, USA 51 Safety"/>
  <result pre="At Risk Population (SHARP) Against COVID-19 Not yet recruiting Coronavirus" exact="infection" post="Hydroxychloroquine adverse reaction Drug: hydroxychloroquine sulfate 200Â mg (mg)"/>
  <result pre="Healthcare Workers Not yet recruiting COVID-19 Diagnostic test: COVID-19 antibodies" exact="testing" post="57 A Clinical Trial of Mycobacterium w in Critically"/>
  <result pre="on the Qt Interval of COVID-19 Coronavirus Infection Recruiting Coronavirus" exact="infection" post="Intensive care patients â€¢ Servicio de Anestesia, Hospital General"/>
  <result pre="COVID-19 in Pregnancy Not yet recruiting COVID-19 2019 novel coronavirus" exact="infection" post="COVID-19 infection â€¢ Chelsea and Westminster Hospital NHS Foundation"/>
  <result pre="Pregnancy Not yet recruiting COVID-19 2019 novel coronavirus infection COVID-19" exact="infection" post="â€¢ Chelsea and Westminster Hospital NHS Foundation Trust, London,"/>
  <result pre="83 Characteristics of COVID-19 Infection Among PREGnant Women Recruiting Coronavirus" exact="infection" post="Pregnancy related Other: COVID-19 positive via testing â€¢ INOVA"/>
  <result pre="Women Recruiting Coronavirus infection Pregnancy related Other: COVID-19 positive via" exact="testing" post="â€¢ INOVA Health System, Falls Church, VA, USA 84"/>
  <result pre="recruiting COVID-19 Drug: tramadol Other: standard care delivered in the" exact="isolation" post="hospitals Hydroxychloroquine is FDA-approved to prevent and treat malaria,"/>
  <result pre="Blood Institute, evaluating the safety and effectiveness of hydroxychloroquine for" exact="treatment" post="of adults hospitalized with COVID-19. The preliminary studies indicate"/>
  <result pre="antiviral action of hydroxychloroquine might be effective in limiting SARS-CoV-2" exact="infection" post="[49, 50]. Further, a combination of hydroxychloroquine and azithromycin"/>
  <result pre="several viruses including coronaviruses showing a strong impact on SARS-CoV" exact="infection" post="[52â€&quot;55]. Moreover, chloroquine and hydroxychloroquine are known to modulate"/>
  <result pre="worked at both entry and post-entry stages of the COVID-19" exact="infection" post="[35]. Currently, we are looking for therapeutic strategies to"/>
  <result pre="infection. A preliminary clinical trial of chloroquine repurposing against SARS-CoV-2" exact="infection" post="has shown some positive results, which led to the"/>
  <result pre="studies demonstrated no significant benefit of hydroxychloroquine drug in COVID-19" exact="treatment" post="[57, 58]. Besides, the clinical trials of a combination"/>
  <result pre="These drugs are used in a fixed-dose combination for the" exact="treatment" post="and prevention of HIV/AIDS [60]. A recent study reported"/>
  <result pre="a COVID-19 patient in Korea were significantly reduced after lopinavir/ritonavir" exact="treatment" post="[61]. In contrast, another clinical trial on hospitalized adult"/>
  <result pre="patients with severe COVID-19 shows no benefit with the lopinavir-ritonavir" exact="treatment" post="[62]. In the past, vaccines were developed against SARS-CoV"/>
  <result pre="world. Additionally, many other options are being explored for the" exact="treatment" post="of COVID-19 patients, including plasma therapy. Recently, convalescence plasma"/>
  <result pre="COVID-19 patients is injected into a severe patient as a" exact="treatment" post="option is explored in India, China, and the USA."/>
  <result pre="Phase 1 Man-made mRNA Eli Lilly Treatment Phase 3 Antibody" exact="treatment" post="GlaxoSmithkline+ Clover Biopharmaceuticals Vaccine Phase 1 Engineering adjuvants with"/>
  <result pre="Vaccine Phase 1 DNA vaccine Johnson &amp;amp; Johnson Vaccine and" exact="treatment" post="Phase 1/2 Deactivated virus Pfizer-BioNTech Vaccine and treatment Phase"/>
  <result pre="Vaccine and treatment Phase 1/2 Deactivated virus Pfizer-BioNTech Vaccine and" exact="treatment" post="Phase 2/3 Has not yet revealed strategy, five-point plan"/>
  <result pre="Pharmaceuticals Treatment Phase 3 Cocktail of antibodies Sanofi Vaccine and" exact="treatment" post="Phase 3 Chimera of RNA viruses, Kevzara drug Takeda"/>
  <result pre="effective therapeutic strategy against SARS-CoV-2. Figure 3 shows the proposed" exact="treatment" post="strategies targeting ACE2 receptors and the receptor-binding domain (RBD)"/>
  <result pre="deploying and marching its armed forces to the site of" exact="infection" post="in the form of the cytokine storm syndrome. This"/>
  <result pre="triggers them. In the first few days of catching any" exact="infection" post="majorly, natural killer cells and macrophages take charge in"/>
  <result pre="of STAT-5 signal transducer, thereby decreasing perforin levels. Thus, a" exact="treatment" post="involving anti IL-6R would be quite effective against COVID-19"/>
  <result pre="immunoglobulin-like receptor genes (KIR genes) and therefore can contain the" exact="infection" post="in the initial stage itself. Thus, Indian populations are"/>
  <result pre="chunk of the population supporting a fragile immune system. Also," exact="isolation" post="alone cannot help, since it is not an indelible"/>
  <result pre="an advantage since it made some people immune to HIV" exact="infection" post="by preventing viral entry. One of the observed trends"/>
  <result pre="this template may act as a remarkable candidate for the" exact="treatment" post="of COVID-19. These may then be packed into exosomes"/>
  <result pre="exosomes and either injected into the blood for multiple organ" exact="treatment" post="or simply inhaled into the lungs through nebulizers. Antiviral"/>
  <result pre="and inhibit signal transduction. However, it is a very costly" exact="treatment" post="and its safety risks need to be tested in"/>
  <result pre="who are frequently exposed to this virus They aim at" exact="screening" post="approximately 1500 COVID-19 recovered patients for identifying and isolating"/>
  <result pre="live and attenuated vaccines train our body to fight against" exact="infection" post="as they are more natural. Some of the limitations"/>
  <result pre="Unfortunately, no therapeutics have yet been proven effective for the" exact="treatment" post="of severe illness caused by SARS-CoV-2. The identification of"/>
  <result pre="is facing a challenge in dealing with a new coronavirus" exact="infection" post="that has just emerged in humans and we are"/>
  <result pre="dependent RNA polymeraseAntivir Res201916910454131233808 40.de WitEFeldmannFCroninJJordanROkumuraAThomasTScottDCihlarTFeldmannHProphylactic and therapeutic remdesivir (GS-5734)" exact="treatment" post="in the rhesus macaque model of MERS-CoV infectionProc Natl"/>
  <result pre="Discov202019314915032127666 44.RainsfordKParkeALClifford-RashotteMKeanWTherapy and pharmacological properties of hydroxychloroquine and chloroquine in" exact="treatment" post="of systemic lupus erythematosus, rheumatoid arthritis and related diseasesInflammopharmacology201523523126926246395"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov202061632194981 50.YaoXYeFZhangMCuiCHuangBNiuPLiuXZhaoLDongESongCZhanSLuRLiHTanWLiuDIn vitro antiviral activity and projection"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
  <result pre="Brouqui P, Raoult D (2020) Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
  <result pre="Agents:105949. 10.1016/j.ijantimicag.2020.105949 52.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGSeidahNGNicholSTChloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J200526916115318 53.RolainJMColsonPRaoultDRecycling of chloroquine and its hydroxyl"/>
  <result pre="V, Barboza JJ, White CM (2020) Hydroxychloroquine or chloroquine for" exact="treatment" post="or prophylaxis of COVID-19: a living systematic review. Ann"/>
  <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
  <result pre="COVID-19 infection in Korea: the application of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J"/>
 </snippets>
</snippetsTree>
